Results 151 to 160 of about 30,845,260 (288)

Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review. [PDF]

Neth Heart J
van Maren SJF, van Doorn EPM, Smits MM, Tack CJJ, van Rossum EFC, El Messaoudi S.   +5 more
europepmc   +1 more source

Eyes on GLP-1 receptor agonists

Journal of the Foundations of Ophthalmology
Glucagon-like peptide-1 (GLP-1) receptor agonists, such tirzepatide and semaglutide, have evolved from specialised diabetes treatments to household brands in recent years. The UK's approach to obesity and type 2 diabetes has changed as a result of its powerful effects on appetite suppression, weight loss, and glycaemic management, with prescriptions ...
openaire   +1 more source

Incretin‐Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency

Obesity, EarlyView.
ABSTRACT Objective Incretin‐based obesity therapies (IBTs), especially GLP‐1 receptor agonists (GLP‐1 RAs), effectively treat obesity and improve comorbidities. However, their impact on energy metabolism is unclear. A recent case of acute generalized muscle weakness in a patient with mitochondrial myopathy after tirzepatide exposure raises concerns ...
Bryn Falahee, Caroline M. Apovian, Nawfal Istfan   +2 more
wiley   +1 more source

The Conventional Cost‐Effectiveness and Distributional Cost‐Effectiveness of Semaglutide for Obesity Treatment

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the conventional and distributional cost‐effectiveness of semaglutide, laparoscopic sleeve gastrectomy (LSG), and a “do nothing” option in Black and White racial subgroups. Methods A Markov simulation model was developed from a healthcare perspective over a 25‐year time horizon for Black and White adults,
Neeti S. Kulkarni, David Hutton, Corwin Rhyan, Jeffrey S. McCullough, Michaela Greenlee, Ankur Pandya   +5 more
wiley   +1 more source

Which heart failure phenotypes benefit from GLP-1 receptor agonists? [PDF]

Cardiovasc Diabetol Endocrinol Rep
Deng J.
europepmc   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Weight Self‐Stigma and Food Noise During Post‐Metabolic Bariatric Surgery Weight Stability

Obesity, EarlyView.
ABSTRACT Objective Food noise has been studied with GLP‐1‐based therapies, but not with metabolic bariatric surgery (MBS), despite shared mechanisms. Data on food noise beyond initial weight loss are limited, and weight self‐stigma (WSS), which links to poorer weight outcomes and risky behaviors after MBS, may relate to higher food noise, especially ...
Dale S. Bond, Yin Wu, Pavlos K. Papasavas, Michael E. Levin, Rebecca M. Puhl, Dahlia Saad‐Pendergrass, Devika Umashanker, Darren Tishler, Jason Lillis   +8 more
wiley   +1 more source

Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists. [PDF]

Diabetes Obes Metab
Chen SC, Wang TJ, Chou CK, Lee C.
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To evaluate glucagon‐like peptide 1 receptor agonists for obstructive sleep apnea compared with controls. Data Sources CINAHL, Cochrane Library, PubMed, and Scopus. Review Methods A PRISMA‐compliant search was conducted from database inception through October 2025.
Cali Loblundo, Sammy Y. Gao, Shaun A. Nguyen, Mohamed Abdelwahab   +3 more
wiley   +1 more source

GLP-1 receptor agonists in cardiovascular disease: a guide for cardiologists. [PDF]

Br J Cardiol
Ayton SL, Papamargaritis D, Davies MJ, McCann GP, Gulsin GS.   +4 more
europepmc   +1 more source